EBOS Group (ASX: EBO) — Stock Profile

About EBOS Group (ASX: EBO)

EBOS Group Limited markets, wholesales, and distributes healthcare, medical, pharmaceutical, and animal care products across Australia, New Zealand, and Southeast Asia. The company operates through two segments, Healthcare and Animal Care, serving a broad range of customers from independent pharmacies and community health providers to veterinary suppliers and pet product retailers.

Within its Healthcare operations, EBOS provides logistics, warehousing, medication management solutions, pharmacy management software, clinical trial logistics and management, product registration services, and health communications consultancy. It also supports independent pharmacies through Pharmacy Choice, an integrated retail program, and the healthSAVE community pharmacy banner. Its product range extends to vitamins, minerals and supplements, herbal teas, natural toothpastes, functional foods including molasses and manuka honey, aesthetic healthcare devices, medical-grade cosmeceuticals, injectables, surgical devices, and medical consumables. The Animal Care segment covers pet nutrition, treats, grooming and clean-up products, and veterinary wholesale. Formerly known as Early Bros Dental and Surgical Supplies Ltd, the company adopted the EBOS Group name in 1986 and traces its incorporation to 1922. It is headquartered in Docklands, Australia.

MFAM Research

No mfam research yet.

Latest Announcements

  • EBOS Group (ASX: EBO) – EBOS Announces Full Year Results
    August 19, 2026
    EBOS Group has completed its largest infrastructure investment program in history and is now positioned to deliver the next phase of value creation for shareholders, following the release of its full year results to 30 June 2026. Revenue grew 9.9% to $13.5 billion and underlying EBITDA expanded 5.0% to $614 million, representing solid top-line momentum […]
  • EBOS Group (ASX: EBO) – Files NZX Distribution Notice 2
    August 19, 2026
    EBOS Group Limited has announced a special distribution totalling NZD $127.3 million (approximately AUD $104.6 million), with shareholders set to receive NZD $0.6150 per share in cash. The distribution, payable on 18 September 2026, will be sourced from retained earnings and represents a material capital return that offers investors insight into the company’s cash generation […]
  • EBOS Group (ASX: EBO) – EBOS Files NZX Results Announcement 2
    August 19, 2026
    EBOS Group delivered mixed results for the twelve months to 30 June 2026, with revenue growth of 9.9% to AUD $13.5 billion providing headline support, but underlying profitability declining 3.1% as significant restructuring and integration costs weighed on the bottom line. The divergence between reported and underlying earnings reveals a company navigating substantial strategic transformation, […]
  • EBOS Group (ASX: EBO) – EBOS Group Files 2025 Annual Report
    August 19, 2026
    EBOS Group delivered a solid FY26 performance, growing revenue 10 percent to $13.5 billion while lifting net profit 4.7 percent to $225.2 million. The result sits comfortably against the backdrop of subdued economic conditions across its major markets in Australia, New Zealand, and Southeast Asia, pointing to the resilience of essential healthcare and animal care […]
  • EBOS Group (ASX: EBO) – Investor Presentation 31 Now Available
    August 19, 2026
    I’m unable to locate the complete FY26 results document with the actual financial figures and operational commentary. The text you provided contains only the disclaimer and risk methodology sections, which isn’t enough to write meaningful analyst commentary. To write the 400-500 word piece, I need: – Revenue figures (actual and growth rate) – EBITDA, EBIT, […]
  • EBOS Group (ASX: EBO) – EBOS Files Appendix 4E Report
    August 19, 2026
    EBOS Group Limited reported revenue of AUD $13.49 billion for the year ended 30 June 2026, up 9.9 percent from AUD $12.27 billion in the prior year, delivering solid topline growth that reflects the company’s position as a leading distributor in the Australasian healthcare and technology sectors. Earnings before depreciation, amortisation, net finance costs and […]
  • EBOS Group (ASX: EBO) – Fuel Cost Pressures Dampen FY26 Earnings
    April 22, 2026
    EBOS Group Limited has downgraded its FY26 earnings guidance due to elevated fuel and energy costs, now expecting underlying EBITDA of $610-$620 million compared to the prior range of $615-$635 million. This represents a reduction of up to $25 million at the midpoint, reflecting an estimated cost impact of $5-10 million that the company has […]

Financial Summary

Price History

Same Industry — HealthcareSame Sub-Industry — Medical Distribution

No other covered stocks.

Share This